Development and functional significance of the pulmonary surfactant system

Cover Page

Cite item

Abstract

Relevance. Prevention of the development of postoperative acute respiratory distress syndrome during operations on the descending thoracic aorta increases the effectiveness of therapy. The study of damage to the surfactant complex during ischemia and reperfusion of the lungs is relevant, since it involves the prophylactic use of the surfactant preparation during operations on the descending part of the thoracic aorta, which are characterized by a high risk of postoperative acute respiratory distress syndrome. Objective: to increase the effectiveness of pharmacological and respiratory therapy of acute respiratory distress syndrome, as well as to identify the role of the surfactant system of the lungs in the onset of inflammation against the background of tuberculosis and the development of regeneration mechanisms that affect the course and outcome of the disease. Materials and Methods. The study involved 24 people, including 14 volunteer patients with a diagnosed respiratory disease in an acute course (while the whole group received the drug from the study as an additional therapy). The sample of 14 people was formed solely due to the compliance of these patients with the criteria that were established before the start of the study of the drug, which had postoperative acute respiratory distress syndrome of various origins in their diagnosis. Results and Discussion. For a comprehensive laboratory determination, an algorithm was used that corresponded to the state standard to identify postoperative acute respiratory distress syndrome. For each participant in the experiments, it was proposed to develop a plan of treatment procedures, taking into account individualization and standardization. Conclusion. Some of the resulting data are collected with respect to the surfactant pulmonary system, which is presented in a compactor model format. A number of basic components are reflected here, which are classified according to cellular and non-cellular factors. At the same time, the surfactant substance helps to reduce the pronounced swelling, which can significantly reduce the process of «sticking» of the alveolar structures during inhalation. All this added up to the normal system of gas metabolism in the lung structures, including the control of the mucociliary system, which acts as a natural stimulator of the function of alveolar macrophages.

About the authors

Ruslan K. Shakhbanov

Dagestan State Medical University

Author for correspondence.
Email: djami_ramazanova@mail.ru
ORCID iD: 0000-0002-3573-2434
Makhachkala, Russian Federation

Madina N. Asadulaeva

Dagestan State Medical University

Email: djami_ramazanova@mail.ru
ORCID iD: 0000-0002-9006-0992
Makhachkala, Russian Federation

Saidat N. Alieva

Dagestan State Medical University

Email: djami_ramazanova@mail.ru
ORCID iD: 0000-0001-6824-2274
Makhachkala, Russian Federation

Alima A. Alimkhanova

Dagestan State Medical University

Email: djami_ramazanova@mail.ru
ORCID iD: 0000-0002-1651-0369
Makhachkala, Russian Federation

References

  1. Kassil VL, Sapicheva YuYu. Acute respiratory distress syndrome and hypoxemia. M. MEDpress-inform. 2016. (In Russian).
  2. Gekkieva OV, Bautin AE, Osovskikh VV, Tregubova IV, Kozetinsky RA, Seiliev AA. and others. Prophylactic use of a surfactant drug in operations on the organs of the chest cavity with a high risk of developing respiratory failure. Doctor.Ru. 2016;12:38—43. (In Russian).
  3. Filonenko TG. The role of surfactant-associated protein SP-A in the local lung defense system. Pathology. 2012;3:117. (In Russian).
  4. Stupak VS, Levkova EA. Theoretical and practical aspects of treating patients at risk in an epidemic of highly pathogenic influenza A / H1N1. Far Eastern Journal of Infectious Pathology. 2010;17:25—27. (In Russian).
  5. Romanenko NA, Bessmeltsev SS, Chechetkin AV. Correction of the immune status of patients with human immunoglobulin for intravenous administration. Kazan Med. magazine. 2017;5:775—783. (In Russian).
  6. Volodin NN, Degtyarev DN, Babak OA, Levadnaya AV. The use of exogenous surfactant in premature infants with bronchopulmonary dysplasia. Vestn. Grew up. State honey. university. 2010;2:41—46. (In Russian).
  7. Vasilyeva IA, Belilovsky EM, Borisov SE, Sterlikov SA. World Health Organization Global Reports on Tuberculosis: Formation and Interpretation. Tuberculosis and Lung Disease. 2017;95(5):7—16.
  8. Yablonsky PK, Vishnevsky BI, Solovieva NS, Manicheva OA, Dogonadze MZ, Melnikova NN, Zhuravlev VYu. Drug resistance of Mycobacterium tuberculosis in different localizations of the disease. Infection and immunity. 2016;6(2):133—140. (In Russian).
  9. Mummadi SR. Clinically significant variability of serum Ig E concentrations in patients with severe astma. J Astma. 2012;4(2):42—47.
  10. Pozdnyakova OYu, Baturin VA. The structure of bacterial infection in patients with bronchial asthma. Kuban Scientific Medical Bulletin. 2012;4(133):80—82. (In Russian).
  11. Lyamina SV, Kruglov SV, Vedenikin TYu. A new strategy for managing the immune response in lung diseases — the role of surfactant protein D as a bivalent factor of macrophage reprogramming. Fundamental Research. 2011;1:90—98. (In Russian).
  12. Ilyin AV. Modern methods of diagnostics of bronchial asthma (literature review). Bulletin of physiology and pathology of respiration. 2012;43:116—123. (In Russian).
  13. Rosenberg OA. Pulmonary surfactant preparations for acute and chronic lung diseases (Part II). General Reanimatology. 2014;10(5):69—86. doi: 10.15360/1813-9779-2014-5-69-86. (In Russian).
  14. Bautin AE, Rosenberg OA, Sumin SA. Acute Respiratory Distress Syndrome. In the book: Sumin S.A., Shapovalov K.G. (ed.). Anesthesiology and resuscitation. M. MIA. 2018. P. 103—109. (In Russian).
  15. Eungdamrong J, Fischer M, Patel R, Meehan S, Sanchez M. Anetoderma secondary to antiphospholipid antibodies. Dermatol Online J. 2012;18(12):26.
  16. Bautin AE, Avdeev SN, Seiliev AA, Shvechkova MV, Merzhoeva ZM, Trushenko NV. Inhalation surfactant therapy in the complex treatment of severe COVID19-pneumonia. Tuberculosis and lung disease. 2020;98(9):6—12. doi: 10.21292/2075-1230-2020-989-6-12. (In Russian).
  17. Ackerman S, Kwatia M, Doyle C. Hydrolysis of Surfactant Phospholipids Catalyzed by Phospholipase A2 and Eosinophil Lysophospholipases Causes Surfactant Dysfunction. Chest. 2003;123:355—361. doi: https://doi.org/10.1378/chest.123.3_ suppl.355S
  18. Lyamina SV. A new strategy for managing the immune response in lung diseases. Therapist. 2011;2;47—48. (In Russian).
  19. Malyshev IYu, Lyamina SV, Shimshelashvili ShL. Functional responses of alveolar macrophages, surfactant protein D and lung disease. Pulmonology. 2011;3;101—107. (In Russian).
  20. Wang J, Shieh C, Yu C. Allergen-induced bronchial inflammation is associated with decreased levels of surfactant proteins A and D in a murine model of asthma. Clin. Exp. Allergy. 2001;31:652—662.

Copyright (c) 2021 Shakhbanov R.K., Asadulaeva M.N., Alieva S.N., Alimkhanova A.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies